Source: Health News

Recently, independent research by the country and a complete new generation of global intellectual property coronary drug-eluting stents in the Netherlands into a European patient successfully opened a cardiac stent domestic market access to developed countries in Europe and America journey.

It is understood that the European debut of "BuMA Supreme biodegradable drug-eluting coronary stent system" by Sino Medical Science and Technology Co., Ltd. developed. In order for the global medical community recognizes "Chinese original" efficacy and strength, benefiting more patients, interventional cardiology in the famous experts under the chairmanship of Prof. Patrick W. Serruys Netherlands Erasmus University, BuMA Supreme bracket PIONEER I clinical trial started in October last year.

BuMA Supreme upgraded version is based on the first generation of products based on the stent material, design, technology, transport systems for a new transformation of the performance was further optimized. Operation of the entire system to use, the performance has been greatly enhanced. Clinical research for global distribution, providing an internationally recognized research data confirm that China will gradually create and produce top-level international high-end products, we can say, BuMA Supreme bracket in the development and production process, are international standards to achieve high